



The Drug Utilization Review Board Reviewed the Following New Drugs and Supplemental Rebate Classes on June 16, 2016

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drug and supplemental rebate class reviews for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL). New drugs and drugs with a recommendation for change in PDL status are highlighted below. The recommendations on all other drugs remained the same as the current PDL status, which is located at <http://dch.georgia.gov/preferred-drug-lists>.

Cystic Fibrosis, Oral Respiratory Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Orkambi (Oral) Tablet*.

Antidiabetics, Long-Acting Insulin Analogs

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Tresiba (Subcutaneous) Injection*.

Pulmonary Hypertension Drugs

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Uptravi (Oral) Tablet* and *Non-Preferred* status with *Prior Authorization and Grandfathering* for *Adcirca (Oral) Tablet*, *Remodulin (Subcutaneous/Intravenous) Injection* and *Tracleer (Oral) Tablet*.

Gastrointestinal, Irritable Bowel Syndrome Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Viberzi (Oral) Tablet*.

Multiple Sclerosis Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Aubagio (Oral) Tablet*, *Betaseron (Subcutaneous) Injection*, and *Gilenya (Oral) Tablet* and *Non-Preferred* status with *Prior Authorization* for *Extavia (Subcutaneous) Injection*.

Anaphylaxis, Epinephrine Pens

The DUR Board recommended *Preferred* status for *Epinephrine (Subcutaneous/Intramuscular) Injection*.

Antidepressants

The DUR Board recommended *No Changes* in the class.



Antidiabetics, GLP-1 Receptor Agonists

The DUR Board recommended **Non-Preferred** status with **Prior Authorization and Grandfathering** for *Tanzeum (Subcutaneous) Injection*.

Antivirals, Antiretrovirals

The DUR Board recommended **Preferred** status for *Descovy (Oral) Tablet* and **Non-Preferred** status with **Prior Authorization and Grandfathering** for *Aptivus (Oral) Capsule and Solution, Complera (Oral) Tablet, Crixivan (Oral) Capsule, Fuzeon (Subcutaneous) Injection, Intelence (Oral) Tablet, Invirase (Oral) Tablet and Capsule, Lexiva (Oral) Tablet and Suspension, Selzentry (Oral) Tablet, Stribild (Oral) Tablet, and Vitekta (Oral) Tablet*. The DUR Board recommended **Non-Preferred** status with **Prior Authorization and Grandfathering** for *Triumeq (Oral) Tablet* with the Board willing to give it a strong recommendation as a preferred agent if Triumeq's manufacturer presents a competitive supplemental rebate offer.

Antipsychotics, Atypical

The DUR Board recommended **Preferred** status with **Prior Authorization** for *Clozapine (Oral) Tablet* and **Non-Preferred** status with **Prior Authorization** for *Rexulti (Oral) Tablet*.

Antipsychotics, Long-Acting Injectables

The DUR Board recommended **Preferred** status with **Prior Authorization** for *all agents in the class*.

Bronchodilators, Anticholinergics

The DUR Board recommended **Non-Preferred** status with **Prior Authorization** for *Spiriva Respimat (Inhalation) Solution*.

Bronchodilators, Steroid-Sympathomimetic Combinations

The DUR Board recommended **Preferred** status for *Dulera (Inhalation) Aerosol*.

Corticosteroids, Oral

The DUR Board recommended **Non-Preferred** status with **Prior Authorization** for *Dexpak (Oral) Tablet*.

Multivitamins, Prenatal

The DUR Board recommended **Preferred** status with **\$30 maximum reimbursement** for *all Prenatal Vitamins with DHA*.

Opioids, Long-Acting Analgesics

The DUR Board recommended **Preferred** status for *Embeda (Oral) Capsule*.